IgA MAb blocks SARS-CoV-2 Spike-ACE2 interaction providing mucosal immunity
M. Ejemel, Q. Li, S. Hou, Z. A. Schiller, A. L. Wallace, A. Amcheslavsky, N. Kurt Yilmaz, J. R. Toomey, R. Schneider, B. J. Close, D.-Y. Chen, H. L. Conway, M. Saeed, L. A. Cavacini, M. S. Klempner, C. A. Schiffer, Y. Wang
Abstract
COVID-19 caused by SARS-CoV-2 has become a global pandemic requiring the development of interventions for the prevention or treatment to curtail mortality and morbidity. No vaccine to boost mucosal immunity or as a therapeutic has yet been developed to SARS-CoV-2. In this study we discover and characterize a cross-reactive human IgA monoclonal antibody, MAb362. MAb362 binds to both SARS-CoV and SARS-CoV-2 spike proteins and competitively blocks hACE2 receptor binding, by completely overlapping the hACE2 structural binding epitope. Furthermore, MAb362 IgA neutralizes both pseudotyped SARS-CoV and SARS-CoV-2 in human epithelial cells expressing hACE2. SARS-CoV-2 specific IgA antibodies, such as MAb362, may provide effective immunity against SARS-CoV-2 by inducing mucosal immunity within the respiratory system, a potentially critical feature of an effective vaccine.
02 /Specification & Classification
Click any tag to browse matching papers- Organism
- Research Focus
- Approach
Reproducibility ledger
Nobody has reported trying to reproduce this paper yet. Did you replicate an experiment or run the code? Your report saves the next lab a week.
Sign in to file a reproducibility report.
Related papers
- Potently neutralizing human antibodies that block SARS-CoV-2 receptor binding and protect animals
S. J. Zost, P. Gilchuk, … J. E. Crowe·bioRxiv·May 22, 2020
- Potent Human Broadly SARS-CoV-2 Neutralizing IgA and IgG Antibodies Effective Against Omicron BA.1 and BA.2
C. Planchais, I. Fernandez, … H. Mouquet·bioRxiv·Apr 1, 2022
- A monoclonal antibody that neutralizes SARS-CoV-2 variants, SARS-CoV, and other sarbecoviruses
P. Wang, R. G. Casner, … D. D. Ho·bioRxiv·Oct 13, 2021
- Neutralizing and protective human monoclonal antibodies recognizing the N-terminaldomain of the SARS-CoV-2 spike protein
N. Suryadevara, S. Shrihari, … J. E. Crowe·bioRxiv·Jan 19, 2021
- Human anti-ACE2 monoclonal antibodies as pan-sarbecovirus prophylactic agents
F. Zhang, J. Jenkins, … P. D. Bieniasz·bioRxiv·Aug 24, 2022
- Potent human neutralizing antibodies elicited by SARS-CoV-2 infection